Direct Thrombin Inhibitors for Diet-Induced Obesity and Fatty Liver Disease

Dec. 12, 2016

Direct Thrombin Inhibitors for Diet-Induced Obesity and Fatty Liver Disease

Technology description

Description of Technology

This NALFD/NASH therapy is achieved using an FDA approved anticoagulant. This drug inhibits the acidity of thrombin, which has been shown to be increased in patients with NALFD. MSU researchers demonstrated that mice fed a high-fat diet while being treated with the anticoagulant significantly reduced morphological and cellular signs of hepatic steatosis. This treatment could be used in the clinic to combat NALFD in obese patients.

Application area

Obesity treatment/prevention
NAFLD treatment/prevention

Advantages

Obesity prevention
NAFLD prevention
Health benefits – the prevention of obesity has significant direct and indirect health benefits
Reduces patient healthcare costs – this is by preventing obesity and NAFLD, which have both direct and indirect health repercussions that require costly medical intervention

由于技术保密工作限制，技术信息无法完全展现，请通过邮箱或短信联系我们，获取更多技术资料。

More information

Institution

Michigan State University

Keywords:

fda approved anticoagulant

msu researchers demonstrated

下载 PDF 文档

Technologies